Oxazolidinones: activity, mode of action, and mechanism of resistance

被引:263
作者
Bozdogan, B [1 ]
Appelbaum, PC [1 ]
机构
[1] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA
关键词
oxazolidinones; mechanism; resistance;
D O I
10.1016/j.ijantimicag.2003.11.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Oxazolidinones are a new group of antibiotics. These synthetic drugs are active against a large spectrum of Gram-positive bacteria, including methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid, the first oxazolidinone available, has already taken its place in the clinic for treatment of Gram-positive infections. Pharmacokinetic properties as well as its good penetration and accumulation in the tissue including bone, lung, vegetations. haematoma and cerebrospinal fluid, allow its use for surgical infections. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 74 条
  • [1] EF-G-dependent GTP hydrolysis induces translocation accompanied by large conformational changes in the 70S ribosome
    Agrawal, RK
    Heagle, AB
    Penczek, P
    Grassucci, RA
    Frank, J
    [J]. NATURE STRUCTURAL BIOLOGY, 1999, 6 (07) : 643 - 647
  • [2] [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
  • [3] The gene encoding the elongation factor P protein is essential for viability and is required for protein synthesis
    Aoki, H
    Dekany, K
    Adams, SL
    Ganoza, MC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) : 32254 - 32259
  • [4] ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW
    APPELBAUM, PC
    [J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) : 77 - 83
  • [5] OXAZOLIDINONES, A NEW CLASS OF SYNTHETIC ANTITUBERCULOSIS AGENT - INVITRO AND INVIVO ACTIVITIES OF DUP-721 AGAINST MYCOBACTERIUM-TUBERCULOSIS
    ASHTEKAR, DR
    COSTAPERIERA, R
    SHRINIVASAN, T
    IYYER, R
    VISHVANATHAN, N
    RITTEL, W
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1991, 14 (06) : 465 - 471
  • [6] Linezolid-resistant enterococci: report of the first isolates in the United Kingdom
    Auckland, C
    Teare, L
    Cooke, F
    Kaufmann, ME
    Warner, M
    Jones, G
    Bamford, K
    Ayles, H
    Johnson, AP
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) : 743 - 746
  • [7] Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid
    Babcock, HM
    Ritchie, DJ
    Christiansen, E
    Starlin, R
    Little, R
    Stanley, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) : 1373 - 1375
  • [8] A multicenter evaluation of linezolid antimicrobial activity in North America
    Ballow, CH
    Jones, RN
    Biedenbach, DJ
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 43 (01) : 75 - 83
  • [9] Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program
    Birmingham, MC
    Rayner, CR
    Meagher, AK
    Flavin, SM
    Batts, DH
    Schentag, JJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) : 159 - 168
  • [10] Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones
    Bobkova, EV
    Yan, YP
    Jordan, DB
    Kurilla, MG
    Pompliano, DL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) : 9802 - 9807